The extremely rapid spread of novel coronavirus disease has now led to over 4 million infections, with limited resources and treatments for this disease. UCI scientists have developed 10 novel formulations for a safe and effective SARS-CoV-2 vaccine, aimed to prevent the development of new cases and the re-infection of those that have recovered.
·For use as a vaccine against SARS-CoV-2 infection and subsequent COVID-19 disease.
·Necessary & Profitable: in order to quell the COVID-19 pandemic, the global population needs a vaccine for immunity against the SARS-CoV-2 virus
·Toxic adjuvant-free: these vaccines are constructed without immune-adjuvants that produce serious side effects
·Protective immunity: antigen sequences are targeted by antibodies within asymptomatic COVID-19 patient blood
·Specificity: these vaccines are comprised of many epitopes instead of whole proteins for a more directed immune response
Globally, over 3.8 million people have contracted SARS-CoV-2 coronavirus to date and over 200,000 have died (5/7/20; coronavirus.jhu.edu). Currently, there are no preventative or therapeutic vaccines for this disease; without a reliable vaccine, immunity is nonexistent for noninfected individuals and continued economic and public health costs are expected. A massive need therefore exists across the world for an effective and safe vaccine.
Researchers at the University of California Irvine recently developed ten candidate vaccines to prevent and treat SARS-CoV-2 infection. These vaccines utilize portions of SARS-CoV-2 proteins that are detected by asymptomatic COVID-19 positive patient antibodies; using this approach, instead of antibodies from severely symptomatic patients, promotes a constructive and specific immune defense without harmful overactivation of the immune system. Additionally, these vaccines overcome serious side effect concerns of previous vaccines by excluding toxic immune adjuvants. This invention is comprised of promising vaccines that could alter the narrative of the COVID-19 pandemic over the next few years.
In vivo: Ten candidate vaccines have been tested for safety and immunogenicity, consisting of specific antibody and cytotoxic T-cell production, in humanized (HLA) transgenic mice and rabbits.